OGT and Intelliseq launch NGS reporting and interpretation for all myeloid malignancy panels

Oxford, UK – 26 October 2023. OGT, A Sysmex Group Company and leading global provider of clinical research solutions, and Intelliseq, a genome informatics company, are delighted to announce the release of GeneSpect™ Somatic Reporter for use with OGT’s SureSeq™ portfolio of next generation sequencing (NGS) panels. This advanced analytical reporting solution pairs state-of-the-art variant interpretation and reporting with OGT’s class-leading NGS panels and bioinformatics solutions. Users of SureSeq Myeloid panels can now benefit from insightful tertiary reporting for all myeloid malignancy content and variants with the GeneSpect Somatic Reporter.

Powered by Intelliseq’s iFlow™ engine, GeneSpect Somatic Reporter presents genomic data and relevant clinical associations in an expert-informed format optimised for the needs of NGS reporting for haematological cancers. iFlow Engine integrates with OGT’s proprietary bioinformatics pipeline to generate clinically relevant variant interpretations, drug and therapy associations, clinical guidelines criteria and clinical trials associations for OGT customers. "NGS has the potential to provide significant insight into cancer research, and clinicians need help deciphering this data" states Adrian Smith, CEO of OGT. "The SureSeq platform partnered with the GeneSpect Somatic Reporter simplifies this critical step, ensuring users maximise the benefits of their NGS data to progress our understanding of cancer."

“GeneSpect’s myeloid reporting solution is the result of an amazing partnership that centres on both our companies’ desire to drive NGS clinical research solutions to the forefront,” says Klaudia Szklarczyk-Smolana, CEO of Intelliseq. “We’ve invested in not only our data infrastructure to enable the delivery of complex clinical insight, but we’ve also partnered with experts to understand the unique needs of providers when it comes to NGS testing in haematology. We are confident that our expert-informed report will save time for both labs and their clients, while still providing best-in-class information, from interpretations to clinical trials.”

In addition to the release of the GeneSpect Somatic Reporter for myeloid malignancies, Intelliseq and OGT also announce they will support reporting for all NGS disease areas offered in the SureSeq portfolio.  SureSeq users will also be able to avail themselves of Intelliseq’s fully customisable report template engine, Customica™ Builder which allows users to customise all aspects of the reporting process, from interpretation through to report rendering. 

GeneSpect Reports and Customica Builder will be presented at the upcoming 2023 Association for Molecular Pathology (AMP) annual meeting in Salt Lake City. OGT will also present data on its latest additional products for myeloid malignancies in a corporate workshop on November 15th, 1:00pm-1:50pm in room 251A, plus host expert sessions at booth #1423.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell^®, CytoSure^® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

CytoSure^®, SureSeq™ and myProbes^®: For Research Use Only, not for use in diagnostic procedures. CytoCell^®: Some products may not be available in your region.

About Sysmex Corporation

Sysmex, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." To realize this vision, Sysmex identifies and verifies prioritized Sustainable Development Goals (SDGs) and materiality (priority issues), thereby maintaining its growth as a company that generates both social and economic value. Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. The company employs more than 10,000 employees worldwide. Sysmex Corporation is listed in the Prime Market on the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

About Intelliseq

Intelliseq is a genome informatics company, focused on the development of novel algorithms and bioinformatics tools devoted to the interpretation of the human DNA sequence. Backed by a team of skilled scientists and bioinformatics experts, their state-of-the-art iFlow™ engine offers tailored solutions for researchers, clinicians, and biotech companies, enabling them to unlock the vast potential of genomic data in personalized medicine and disease research. The system drives lab efficiency through streamlined raw DNA data-to-reporting workflows in a variety of genome medicine applications.

For more information on Intelliseq, please visit https://intelliseq.com/